Learn why "life years saved" better captures progress in blood cancer than 5-year survival rates, with insights from Dr. E. Anders Kolb of Blood Cancer United.

Early results from the phase 2 RESTORE-PV trial suggest that the investigational monoclonal antibody DISC-3405 has the ...

Over the past year alone, 4 major clinical trials have redefined frontline HSPC management. ARANOTE ( NCT02799602) v alidated ...

Purpose-built decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials ...

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.

In the patient-only intervention group, the rate of skin self-examination and physician skin examination increased from 15.8% at baseline to 47.5% at 12 months; in the group that also had outreach to ...

SOHO-01 used blinded independent central review per RECIST v1.1 and enrolled locally advanced/metastatic nonsquamous NSCLC ...

An interim analysis of a phase 2b trial (NCT04974008) showed a 3-year OS rate of 71.2% among OST-HER2–treated patients compared with 45.8% in a comparable combined historical control group (90% CI, 11 ...

Sex-stratified outputs showed similar overdiagnosis proportions but higher absolute rates in women, yielding an estimated 443 ...

Martin Dietrich, MD, PhD, says the first move at progression is to extend frontline therapy rather than abandon it, looking ...

Wade Iams, MD, says progression-free survival (PFS) drives his frontline choice, since median overall survival remains years ...

Dr Shubham Pant outlines what's next for daraxonrasib in pancreatic cancer, including the RASolute 303 and RASolute 304 ...